阿姆斯特丹国际共识会议:新辅助治疗后切除胰腺癌的病理肿瘤反应评分
Histopathologically scoring the response of pancreatic ductal adenocarcinoma (PDAC) to neoadjuvant treatment can guide the selection of adjuvant therapy and improve prognostic stratification.…
要点
- TRS应评估残留存活肿瘤负荷而非肿瘤消退。
- CAP评分系统目前最合适但需客观化其分类标准。
- 需验证改进后的共识评分系统并明确组织采样要求。
核心结论
- 共识认为TRS提供新辅助治疗效果的独特信息,应评估残留存活肿瘤负荷。
- CAP评分系统目前最合适,但需将「minimal」「extensive」等主观术语替换为客观标准。
主要发现
- 共识(≥80%同意)共七项,包括TRS重要性、评估残留存活肿瘤负荷、CAP系统最合适、改进CAP分类标准、验证改进系统、确定组织采样范围、发表时详述采样范围。
关键数值与推荐
- 共识(≥80%同意)共七项:TRS重要;评估残留存活肿瘤负荷;CAP系统最合适;改进CAP分类标准;验证改进系统;确定组织采样范围;发表时详述采样范围。
临床怎么用
- 病理评估应报告残留存活肿瘤负荷而非肿瘤消退。
- 目前可采用CAP评分系统,但需注意其分类标准的主观性。
- 发表研究时应在材料与方法中详细描述组织采样范围。
局限性
- 共识基于专家意见(≥80%同意),改进的评分系统尚需回顾性和前瞻性验证。
- 组织采样范围需前瞻性研究确定,需考虑肿瘤反应的异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histopathologically scoring the response of pancreatic ductal adenocarcinoma (PDAC) to neoadjuvant treatment can guide the selection of adjuvant therapy and improve prognostic stratification. However, several tumor response scoring (TRS) systems exist, and consensus is lacking as to which system represents best practice. An international consensus meeting on TRS took place in November 2019 in Amsterdam, The Netherlands. Here, we provide an overview of the outcomes and consensus statements that originated from this meeting. Consensus (≥80% agreement) was reached on a total of seven statements: (1) TRS is important because it provides information about the effect of neoadjuvant treatment that is not provided by other histopathology-based descriptors. (2) TRS for resected PDAC following neoadjuvant therapy should assess residual (viable) tumor burden instead of tumor regression. (3) The CAP scoring system is considered the most adequate scoring system to date because it is based on the presence and amount of residual cancer cells instead of tumor regression. (4) The defining criteria of the categories in the CAP scoring system should be improved by replacing subjective terms including "minimal" or "extensive" with objective criteria to evaluate the extent of viable tumor. (5) The improved, consensus-based system should be validated retrospectively and prospectively. (6) Prospective studies should determine the extent of tissue sampling that is required to ensure adequate assessment of the residual cancer burden, taking into account the heterogeneity of tumor response. (7) In future scientific publications, the extent of tissue sampling should be described in detail in the "Materials and methods" section.
引用
- Janssen BV, Tutucu F, van Roessel S, et al. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod Pathol. 2020. PMID: 33041332. doi:10.1038/s41379-020-00683-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。